JAK Inhibitor denied for missing prior authorization by Cigna?

Cigna's specific coverage criteria for jak inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Requires Prior Authorization for JAK Inhibitors — and What to Do When It Is Denied

Prior authorization (PA) for JAK inhibitors is standard practice at Cigna. The insurer requires advance clinical review before covering these medications because they are high-cost specialty drugs with defined clinical entry criteria. A prior-auth denial is not the same as a final coverage denial — it is the beginning of a reviewable process.

## Why This Denial Happens

Cigna's prior-authorization process for JAK inhibitors checks that the submitted clinical information satisfies the plan's coverage criteria: confirmed diagnosis, documented disease severity, and evidence that required earlier therapies have been tried or are not appropriate. Denials at the PA stage most often occur because the submitted request lacked sufficient clinical detail — not because coverage is genuinely unavailable.

## Your Appeal Rights

A prior-authorization denial is an adverse benefit determination and carries full appeal rights:

• ERISA §503: for employer-sponsored plans, you are entitled to a full-and-fair review and to receive the specific criteria used in the denial decision.
• ACA §2719 External Review: after exhausting the internal appeal (or if the plan is non-grandfathered), you may request independent external review. The external-review window is typically approximately four months from the final adverse determination — verify the exact date on your denial letter. An expedited option (often 72-hour turnaround) is available when a standard timeline would seriously jeopardize your health.
• Expedited / concurrent review: if you are already on the medication or your condition is acute, request expedited prior-auth review.

## Concrete Appeal Process

1. Read the denial letter carefully — it must specify the exact criteria your request did not satisfy. 2. Request Cigna's full prior-authorization criteria for JAK inhibitors; you are entitled to this document. 3. File the internal appeal within the stated timeframe (commonly 180 days for post-service; check your denial letter for pre-service deadlines). 4. Supplement the original PA submission with the documentation gaps identified in the denial. 5. If internal appeal fails, request external review promptly.

## Documentation to Gather

• Diagnosis confirmation: specialist evaluation notes, relevant diagnostic studies, and ICD codes.
• Prior-treatment history: a chronological, outcome-annotated record of every treatment tried before the JAK inhibitor, with start/stop dates and documented reasons for discontinuation or inadequacy.
• Clinical severity at current visit: objective disease-activity measures and functional assessments recorded in the chart.
• Prescriber medical-necessity letter: a comprehensive letter linking the patient's clinical picture to the specific PA criteria, referencing the FDA-approved prescribing label and the relevant specialist-society guideline.

## Criteria-Mapping Structure

Obtain Cigna's PA criteria document and the FDA-approved prescribing information for the specific JAK inhibitor. Build a checklist: each PA criterion on the left, the supporting chart evidence (with date and source) on the right. Submit this as an exhibit to the appeal so the reviewer can verify compliance criterion by criterion.